Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study

Introduction Randomized clinical trialsshowed that vildagliptinis well tolerated and leads to clinically meaningful decreases in glycated hemoglobin(HbA1c) and fasting plasma glucose (FPG) both in monotherapy and as add-on therapy in inadequately controlled type 2 diabetes mellitus (T2DM) patients. Nevertheless, there is an increased interest for real-life studies to confirm the clinical trialfindings in the setting of a daily clinical practice. The aim of this study was to evaluate the effectiveness and tolerability of vildagliptinin a real-life clinical setting and to explore factors determining drug adherence and T2DM management.